Pharmacogenomics. Edition No. 2

  • ID: 4519360
  • Book
  • 544 Pages
  • Elsevier Science and Technology
1 of 4

Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation, Second Edition, provides comprehensive coverage of the challenges and opportunities facing the therapeutic implications of pharmacogenomics from academic, regulatory, pharmaceutical, socio-ethical and economic perspectives. While emphasis is on the limitations in moving the science into drug development and direct therapeutic applications, this book also focuses on clinical areas with successful applications and important initiatives that have the ability to further advance the discipline. New chapters cover important topics such as the challenge of integrating epigenetics into pharmacogenomics research, pharmacoeconomics, cost-effectiveness and reimbursement. Ethnicity and ethno-bridging in translating and implementing scientific findings worldwide is also discussed.

With chapters written by interdisciplinary experts and insights into the future direction of the field, this book is an indispensable resource for academic and industry scientists, graduate students and clinicians engaged in pharmacogenomics research and therapeutic implementation.

  • Provides viewpoints that focus on the scientific and translational challenges and opportunities associated with advancing the field of pharmacogenomics
  • Highlights progress in both the research and clinical areas of pharmacogenomics, as well as relevant implementation experience, challenges, and perspectives on direct-to-consumer genetic testing
  • Includes discussion points, review questions, and cases for self-assessment purposes and to facilitate in-depth discussion
Note: Product cover images may vary from those shown
2 of 4

1. Principles of Pharmacogenomics: Pharmacokinetic, Pharmacodynamic, and Clinical Implications 2. Governmental and Academic Efforts to Advance the Field of Pharmacogenomics 3. Molecular Approaches, Models, and Techniques in Pharmacogenomic Research and Development 4. Study Designs in Pharmacogenomics Research 5. Incorporating Pharmacogenomics in Drug Development: Industry and Regulatory Perspectives 6. Translating Pharmacogenomic Research to Therapeutic Potentials
Ethical Considerations and Challenges in Pharmacogenomics 7. Pharmacogenomics in Cancer Therapeutics 8. Pharmacogenomics in Cardiovascular Diseases
Lessons Learned from Warfarin 9. Pharmacogenomics in Psychiatry Disorders
Lessons Learned from Antidepressants and Antipsychotics 10. Role of Pharmacogenomics in HIV Infection
Lessons Learned from Efavirenz 11. Role of Pharmacogenomics in Diabetes
Lessons Learned from Metformin? 12. A Look to the Future: Pharmacogenomics, Pharmacoepigenomics, and System Biology
Data Technologies of Today and Tomorrow 13. The Importance of Race and Ethnicity in Pharmacogenomics 14. Reactive, Point-of-Care, Pre-emptive and Direct-to-Consumer Pharmacogenomic Testing 15. Cost-effectiveness and Pharmacogenomic Testing Reimbursement 16. Pharmacogenomics Education and Clinical Practice Guidelines

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Lam, Yui-Wing Francis
Dr. Lam is Professor of Pharmacology at the University of Texas Health Science Center San Antonio (UTHSCSA). His editing experience included the first edition of Pharmacogenomics as well as being the lead editor of another published book entitled "Herbal Supplements - Drug Interactions. Scientific and Regulatory Perspectives”. He is also a co-author for a book chapter on pharmacogenetics in six consecutive editions of the textbook "Pharmacotherapy: A Pathophysiologic Approach”. Dr. Lam designed and continues to direct a graduate course "Molecular and Pharmacological Basis of Therapeutics” since 2002 for the UTHSCSA and the College of Pharmacy at the University of Texas at Austin. He has organized and participated in international and national symposia on topics related to personalized and molecular medicine, and is a scientific councilor for the Pacific Rim Association for Clinical Pharmacogenetics.
Stuart, Scott R.
Dr. Stuart Scott will take on the co-editor role for this second edition. Dr. Scott is an Assistant Professor in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, New York, where he oversees clinical pharmacogenetic testing as an ABMGG-certified Director of the Mount Sinai Genetic Testing Laboratory. His research interests include cardiovascular pharmacogenomics, multiethnic pharmacogenomic allele discovery, and long-read sequencing method development. He has co-authored Clinical Pharmacogenetics Implementation Consortium (CPIC) practice guidelines and is a member of other international genomics/pharmacogenomics consortia, and is a co-investigator of the Institute for Personalized Medicine (IPM) pharmacogenomics implementation program at Mount Sinai. He teaches pharmacogenetics to medical, graduate and genetic counseling students, clinical residents and fellows, and co-directs the comprehensive Translational Genomics graduate level course at Mount Sinai.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll